BioNTech

BioNTech SE (ˈbaɪɒnˌtek) is a German biotechnology company dedicated to the creation of active immunotherapies for treatments of serious diseases.

BioNTech headquarters in An der Goldgrube street, Mainz

BioNTech SE
Company typePublic (SE)
NASDAQ: BNTX
ISINUS09075V1026
IndustryBiotechnology
Founded2008 (2008)
Founders
  • Uğur Şahin
  • Özlem Türeci
  • Christoph Huber
  • Andreas Strüngmann
  • Thomas Strüngmann
  • Michael Motschmann
  • Helmut Jeggle
Headquarters
Mainz
,
Germany
Number of locations
8 (2022)
Area served
Worldwide
Key people
  • Uğur Şahin (CEO)
  • Özlem Türeci (CMO)
  • Sean Marett (CBO, CCO)
  • Sierk Poetting (CFO, COO)
  • Ryan Richardson (CSO)
ProductsBNT162b2
ServicesImmunotherapy
RevenueDecrease €17.3 billion (2022)
Decrease €12.6 billion (2022)
Decrease €9.43 billion (2022)
Total assetsIncrease €23.3 billion (2022)
Total equityIncrease €20.1 billion (2022)
Number of employees
Increase 4,530 (2022)
Websitebiontech.com
Footnotes / references
Biontech FY 2022 report[1]

It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases.[2] In 2020, the company started developing the BNT162b2 vaccine against SARS-CoV-2 with Pfizer[3] and Fosun.[4][5] In late 2020 BioNTech successfully developed, together with Pfizer, the RNA vaccine called BNT162b2 against COVID-19. The company said, it's vaccine efficacy was 95%. On 2 December 2020, the United Kingdom government gave permission to use BNT162b2 vaccinations in the country.[6] Later in December 2020 USA,[7] Canada[8] and the EU[9] also gave permission to use the BioNTech vaccine.

References
  1. "BioNTech 2022 Annual Report (Form 20-F)". U.S. Securities and Exchange Commission. 27 March 2023. Retrieved 24 June 2023.
  2. Form F-1 BioNTech SE (Report). U.S. Securities and Exchange Commission. 9 September 2019. Archived from the original on 14 February 2021. Retrieved 13 October 2019.
  3. Lovelace Jr., Berkeley (27 July 2020). "Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday". CNBC. Retrieved 2 August 2020.
  4. "BioNTech in China alliance with Fosun over coronavirus vaccine candidate". Reuters. Frankfurt. 15 March 2020. Retrieved 2 August 2020.
  5. Burger, Ludwig (22 April 2020). "Germany approves trials of COVID-19 vaccine candidate". Reuters. Berlin. Retrieved 2 August 2020.
  6. "UK medicines regulator gives approval for first UK COVID-19 vaccine". GOV.UK. 2 December 2020. Retrieved 25 January 2021.
  7. Commissioner, Office of the (7 January 2021). "Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions". FDA.
  8. Canada, Health (9 December 2020). "Pfizer-BioNTech COVID-19 vaccine: What you should know". aem. Retrieved 25 January 2021.
  9. "Commission approves BioNTech/Pfizer vaccine". POLITICO. 21 December 2020. Retrieved 25 January 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.